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Abstract
Introduction: High mobility group box 1 protein (HMGB1) is a nuclear DNA binding protein acting as a pro-
inflammatory mediator following extracellular release. HMGB1 has been increasingly recognized as a pathogenic
mediator in several inflammatory diseases. Elevated serum levels of HMGB1 have been detected in autoimmune
diseases including Systemic lupus erythematosus (SLE). However, the local expression of HMGB1 in active lupus
nephritis (LN) is not known. Here we aimed to study both tissue expression and serum levels of HMGB1 in LN
patients with active disease and after induction therapy.
Methods: Thirty-five patients with active LN were included. Renal biopsies were performed at baseline and after
standard induction therapy; corticosteroids combined with immunosuppressive drugs. The biopsies were evaluated
according to the World Health Organization (WHO) classification and renal disease activity was estimated using the
British Isles lupus assessment group (BILAG) index. Serum levels of HMGB1 were analysed by western blot. HMGB1
expression in renal tissue was assessed by immunohistochemistry at baseline and follow-up biopsies in 25 patients.
Results: Baseline biopsies showed WHO class III, IV or V and all patients had high renal disease activity (BILAG A/B).
Follow-up biopsies showed WHO I to II (n = 14), III (n = 6), IV (n = 3) or V (n = 12), and 15/35 patients were
regarded as renal responders (BILAG C/D).
At baseline HMGB1 was significantly elevated in serum compared to healthy controls (P < 0.0001). In all patients,
serum levels decreased only slightly; however, in patients with baseline WHO class IV a significant decrease was
observed (P = 0.03). Immunostaining revealed a pronounced extranuclear HMGB1 expression predominantly
outlining the glomerular endothelium and in the mesangium. There was no clear difference in HMGB1 expression
comparing baseline and follow-up biopsies or any apparent association to histopathological classification or clinical
outcome.
Conclusions: Renal tissue expression and serum levels of HMGB1 were increased in LN. The lack of decrease of
HMGB1 in serum and tissue after immunosuppressive therapy in the current study may reflect persistent
inflammatory activity. This study clearly indicates a role for HMGB1 in LN.
Introduction
Systemic lupus erythematosus (SLE) is a chronic inflam-
matory autoimmune disease characterized by multiple
organ involvement, production of autoantibodies to
nuclear components, and immune complex deposition
[1]. Lupus nephritis (LN) is regarded as one of the most
severe organ manifestations of SLE, affecting approxi-
mately 35% to 50% of patients with lupus. Despite
increased knowledge of pathogenesis and improved
treatment regimens, LN remains a main cause of mor-
bidity among patients with SLE [2].
High-mobility group box 1 protein (HMGB1), a
nuclear protein found in all mammalian cells, is known
as a DNA-binding protein participating in chromatin
structure and transcriptional regulation [3,4]. Extracellu-
lar HMGB1 has been identified as a proinflammatory
mediator and, owing to its proinflammatory and immu-
nostimulatory properties, has been proposed to contri-
bute to the pathogenesis of multiple chronic
inflammatory and autoimmune diseases [5-8]. HMGB1
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is actively secreted from activated immune cells such as
macrophages and monocytes and is passively released
from injured or necrotic cells. When translocated from
the nucleus to the extracellular milieu, HMGB1 can act
as an ‘alarmin’, a danger signal that can activate the
immune system and has been demonstrated as a key
factor in necrosis-induced inflammation [9,10]. More-
over, HMGB1 induces other cytokines such as tumor
necrosis factor and interleukin-1 (IL-1), IL-6, and IL-8
and is an activator of endothelial cells leading to the
upregulation of adhesion molecules [11,12].
Elevated serum levels of HMGB1 have been found in
different inflammatory conditions such as sepsis [13],
rheumatoid arthritis [14,15], anti-neutrophilic cytoplas-
matic antibody (ANCA)-associated vasculitis [16], and
chronic kidney disease [17] as well as in SLE [18-20].
Previous studies have shown increased HMGB1 expres-
sion in skin lesions of patients with SLE [21], thus indi-
cating that HMGB1 may be an important mediator of
inflammation in target organs in lupus.
Interestingly, increased levels of HMGB1 were recently
demonstrated in patients with active LN in comparison
with patients with active non-renal disease [22]. How-
ever, specified data on the severity of renal disease, his-
topathological findings, or tissue expression were not
included in that study. The aim of this study was to
investigate renal tissue expression and serum levels of
HMGB1 in correlation not only with renal histopatholo-
gical and clinical activity but also with response to ther-




Thirty-five patients with SLE and biopsy-proven active
LN during the period of 1996 to 2008 were included in
this study. All patients fulfilled the 1982 American Col-
lege of Rheumatology classification criteria for SLE [23]
and participated in a prospective control program for
LN at the rheumatology clinic of Karolinska University
Hospital in Stockholm, Sweden. Thirty of the 35
patients were female (86%) and five were men (14%),
and the mean age was 34 years (range of 18 to 50). The
patients were treated, in accordance with standard ther-
apy for LN, with corticosteroids combined with cyclo-
phosphamide (n = 21), mycophenolate mofetil (n = 8),
or rituximab (n = 5), and one patient was treated with
azathioprin. After induction therapy for a mean duration
of 8 months (range of 6 to 14), all patients underwent a
second renal biopsy. At both biopsies, clinical data and
blood and urinary samples were collected. Serum sam-
ples were frozen at -70°C for future analyses. As a con-
trol group for serum levels of HMGB1, blood samples
from 48 healthy controls were used [17]. The clinical
characteristics of patients and nephritis data at baseline
and follow-up are presented in Table 1.
Evaluation of renal function, histopathology, and renal
activity
Renal evaluation at the time point of the first and sec-
ond biopsies included urine analyses (dipslide proce-
dure), urinary sediment assessment, and investigation of
24-hour urine albumin excretion. Renal function was
determined by serum creatinine levels (expressed as
micromoles per liter) and estimated glomerular filtration
rate (GFR) by using the modification in diet in renal dis-
ease (MDRD) formula [24].
Renal biopsies were performed by percutaneous ultra-
sonography-guided puncture. The renal tissue obtained
was evaluated by light microscopy, immunofluorescence,
and electron microscopy. The biopsies were graded
according to the World Health Organization (WHO)
classification of nephritis [25] and additionally scored
for activity and chronicity indices [26]. Renal tissue
Table 1 Clinical characteristics of all patients at baseline
and follow-up
Baseline Follow-up
Creatinine, μmol/L 92.3 (46.6) 81.6 (42.6)
Proteinuria, g/day 2.0 (1.8) 0.7 (0.8)
C3, g/L 0.53 (0.23) 0.80 (0.23)
C4, g/L 0.09 (0.06) 0.13 (0.07)
C1q 66.6% (41.0%) 75.2% (29.5%)
Anti-dsDNA-positivea 83% 44%
Glomerular filtration rate 80.7 (29.4) 88.6 (26.4)
U-erythrocytes > 1+ 79% 46%
Renal histology, number
Class I 15 1
Class II 12 13
Class III 2 6
Class IV 6 3
Class III/V 12
Class V
Activity index 5.7 (3.1) 2.5 (2.3)











Values are presented as mean (standard deviation) unless otherwise indicated.
aAnti-double-stranded DNA (anti-dsDNA) raised to at least 1:25. BILAG, British
Isles lupus assessment group.
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from an unaffected part of a kidney that was nephrecto-
mized owing to carcinoma was used as control. Evalua-
tion of renal activity was estimated by using the British
Isles lupus assessment group (BILAG) index [27,28].
Patients with renal BILAG C or D at follow-up were
regarded as responders (as previously suggested [29]).
Serology and complement measures
Assessments of serum IgG anti-double-stranded DNA
(anti-dsDNA) antibodies were carried out by immuno-
fluorescence microscopy by using Crithidiae luciliae as
a source of antigen. Analyses of complement component
C1q were performed by rocket electrophoresis by using
rabbit anti-C1q as the antibody. Levels of C1q were
expressed as the percentage of the levels of healthy
blood donors (normal range of 76% to 136%). C3 (nor-
mal range of 0.67 to 1.43 g/L) and C4 (normal range of
0.12 to 0.32 g/L) levels were determined by
nephelometry.
HMGB1 serum determination
HMGB1 was analyzed by Western blot in sera from 20
of the patients at baseline and at repeat biopsy by a
method previously described [17].
Immunohistochemical staining of renal biopsies
Immunohistochemical stainings of HMGB1 expression
were performed on formaldehyde-fixed paraffin-
embedded serial 4-μm sections of renal biopsies. Slides
were deparaffinized in xylene and rehydrated with etha-
nol. Antigen retrieval treatment prior to staining was
omitted to allow clearer visualization of extranuclear
HMGB1. To block endogenous peroxidase activity, sec-
tions were treated with 3% H2O2 followed by a serum
block with 2% human AB sera for 30 minutes and an
avidin/biotin-blocking step (Vector Laboratories Inc.,
Burlingame, CA, USA). The slides were thereafter incu-
bated overnight with an affinity-purified monoclonal
mouse IgG2b anti-HMGB1 antibody (concentration of
10 μg/mL, 2G7; Critical Therapeutics Inc., Lexington,
MA, USA). A biotin-labeled horse anti-mouse antibody
(Vector Laboratories Inc.) containing 2% normal horse
serum was used for detection. Stainings were developed
by using a DAB kit (Vector Laboratories Inc.) in accor-
dance with the instructions of the manufacturer. Sec-
tions were counterstained with Mayer’s hematoxylin.
Phosphate-buffered saline supplemented with 0.1% sapo-
nin was used in all subsequent washes and incubation
steps in order to permeabilize the cells. In each assay,
controls for specificity of the HMGB1 staining were
included on the basis of parallel staining studies omit-
ting the primary antibody, and a primary isotype-
matched immunoglobulin of irrelevant antigen specifi-
city (negative mouse IgG2b control; Dako Cytomatation,
Glostrup, Denmark) was used. The specificities of extra-
cellular and intracellular HMGB1 immunoreactivities
were further verified by blocking experiments with pre-
absorption of the HMGB1-specific antibody with recom-
binant HMGB1 prior to staining.
Statistics
For comparisons of variables at baseline and at repeat
biopsy, the non-parametric Wilcoxon matched pair test
was used. For comparisons of variables between groups,
the non-parametric Mann-Whitney test was used. Cor-
relations were calculated by using Spearman’s rank cor-
relation. P values of less than 0.05 were considered
statistically significant. Statistical evaluation was made
with statistical software (STATISTICA 9; StatSoft, Inc.,
Tulsa, OK, USA).
Ethics
Informed consent was obtained from all subjects, and
the study protocol was approved by the regional ethics
committee in Stockholm.
Results
Histopathology and renal activity
All patients had an active nephritis at baseline; biopsies
showed WHO class III (n = 15), III/V (n = 2), IV (n =
12), or V (n = 6). All patients had high renal disease
activity; 32 out of 35 had renal BILAG A and three out
of 35 a BILAG B. Follow-up biopsies showed WHO I (n
= 1), II (n = 13), III (n = 6), IV (n = 3), or V (n = 12).
Two out of 35 patients had renal BILAG A, 18 out of
35 BILAG B, seven out of 35 BILAG C, and eight out of
35 BILAG D. Fifteen patients were thus regarded as
responders and 20 out of 35 were regarded as non-
responders according to BILAG. The mean renal activity
index decreased significantly from 5.7 to 2.5 (P < 0.001),
whereas no significant findings regarding chronicity
index were observed (data presented in Table 1).
HMGB1 serum determination and evaluation of renal
activity
At baseline, HMGB1 was significantly elevated in the
patient group (mean of 108.4 ± 48.0 ng/mL, median of
117.1, range of 19.8 to 202.4) in comparison with
healthy controls (mean of 13 ± 10 ng/mL, median of
12.0, range of 0 to 38.0) (P < 0.0001) (Figure 1). Serum
HMGB1 levels were significantly higher in the patients
with WHO class III (mean of 133.8 ± 47.2 ng/mL, med-
ian of 130.0, range of 29.6 to 202.0) in comparison with
those with class IV (mean of 87.7 ± 39.1 ng/mL, median
of 87.7, range of 19.8 to 155.9) (P = 0.01). When all
patients were examined, there was at trend toward
slightly decreased HMGB1 levels at follow-up (mean of
101.7 ± 50.7 ng/mL, median of 99.7, range of 27.9 to
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183.9) (P value not significant), although the levels
remained significantly high in comparison with those of
the control group (P < 0.0001) (Figure 1). In the patients
with WHO class III at baseline biopsy, no difference in
HMGB1 levels was observed at follow-up (mean of
136.9 ± 42.9 ng/mL, median of 142.7, range of 40.3 to
183.9), whereas in class IV, a significant decrease was
found (mean of 71.0 ± 35.6 ng/mL, median of 71.4,
range of 27.9 to 145.9) (P = 0.03) (Figure 2).
The responder patients (BILAG C/D) had lower serum
levels of HMGB1 at follow-up (mean of 93.7 ± 54.2 ng/
mL, median of 94.0, range of 27.9 to 181.5) versus those
with persisting renal BILAG A or B (mean of 107.4 ±
49.0 ng/mL, median of 108.8, range of 40.3 to 183.9),
but the difference was not statistically significant (Figure
3). Though not statistically significant, the serum levels
were higher at follow-up in the group of patients (n =
4) who developed membranous nephritis (WHO V) in
comparison with other WHO classes at follow-up
biopsy. There was an inverse correlation between activ-
ity index at baseline biopsies and HMGB1 levels both at
baseline (r = -0.61, P < 0.05) and at follow-up (r = -0.58,
P < 0.05). HMGB1 showed no significant correlation
with complement levels, creatinine, GFR, proteinuria, or
anti-dsDNA antibody positivity (data not shown). Data
on serum levels of HMGB1, WHO classification, protei-
nuria, and renal function are presented in Table 2.
Immunohistochemistry
Immunostaining revealed an extranuclear HMGB1
expression found in all of the examined biopsies from
the patients with LN. The staining was predominantly
found outlining the glomerular endothelium and was
also documented in the mesangium. A less pronounced
HMGB1 expression was documented in vessels and tub-
ular cells (Figure 4). To investigate the amount of
HMGB1 expression, an arbitrary scale was used for
comparisons between biopsies. Five patients had
unchanged amounts, eight had a decrease, and 12 had
more abundant amounts of HMGB1 staining. Overall,
no difference in the comparison of first and second
biopsies was demonstrated (data not shown), and no
clear correlation with histopathological classification or
clinical outcome could be documented.
HMGB1 is abundantly present in all cell nuclei, thus
generating a strong expression that might interfere with
visualization of a cytoplasmatic and extranuclear stain-
ing, which most often is weaker. By omission of antigen
retrieval treatment prior to staining, a clearer visualiza-
tion of extranuclear HMGB1 expression is allowed. In
Figure 1 HMGB1 was significantly elevated in serum of lupus nephritis patients compared with healthy controls. Serum levels of
HMGB1 (expressed as nanograms per milliliter) at baseline and follow-up in lupus nephritis patients (n = 20) and controls (n = 48). Data are
expressed as medians, boxes show 25th to 75th percentiles, and median values are marked inside the boxes. HMGB1, high-mobility group box 1
protein; ns, not significant.
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kidney biopsies from control renal tissue, HMGB1
expression was predominantly negative or, if present,
was restricted to the cell nuclei (Figure 4).
Discussion
To the best of our knowledge, we are the first to
demonstrate HMGB1 expression in affected renal tissue
from LN patients, in whom we clearly show an
increased expression in active disease as well as after
immunosuppressive therapy. HMGB1 tissue stainings
were predominantly found outlining the glomerular
endothelium but also were expressed in the mesangium.
In this study, we could also confirm the findings of ele-
vated serum levels of HMGB1 in LN measured by
Figure 2 Serum HMGB1 levels in different World Health Organization (WHO) classes. Serum levels at baseline and follow-up in lupus
nephritis patients with WHO III (n = 9) versus IV (n = 11) are shown. After induction therapy, serum levels of HMGB1 were significantly
decreased in patients with WHO class IV. However, HMGB1 levels remained unchanged in patients with WHO class III. Data are expressed as
means, and vertical bars denote 95% confidence intervals. HMGB1, high-mobility group box 1 protein.
Figure 3 Serum levels of HMGB1 of responders and non-responders at baseline and follow-up. Patients with renal BILAG (British Isles
lupus assessment group) C or D at follow-up were regarded as responders. In non-responding patients, serum levels of HMGB1 remained high
at follow-up. Though not statistically significant, a clear trend of decreasing serum HMGB1 was documented in patients who responded to
induction therapy. Data are expressed as means, and vertical bars denote 95% confidence intervals. HMGB1, high-mobility group box 1 protein.
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Western blot, as recently shown by Abdulahad and col-
leagues [22].
We found a clear tissue staining for HMGB1 in LN
and this staining was absent in non-lupus control renal
tissue. There was no distinct difference in expression of
HMGB1 either in the proliferative glomerular lesions or
in sites with infiltrates of inflammatory cells in compari-
son with less affected glomeruli, and the exact origin of
the increased renal expression of HMGB1 is not fully
clear. The staining outlining the glomerular endothelium
could emanate from local extracellular release but also
may reflect capture from circulating HMGB1. Thus, one
may speculate that the findings of increased serum
levels as well as tissue expression of HMGB1 reflect
both systemic and local inflammation within the kidney.
In glomeruli, the pronounced endothelial staining and
the increased expression in the mesangium suggest a
co-localization for HMGB1 and immune depositions in
LN. However, further studies with other methodologies
are required to address this issue.
Elevated HMGB1 expression has previously been
demonstrated in lupus patients with cutaneous photoin-
duced inflammation, in whom cytoplasmatic and extra-
cellular HMGB1 were detected in biopsies from the
most clinically active skin lesions in comparison with
inactive or non-lesional skin [21]. That study also
demonstrated that HMGB1 was still expressed in
persisting dermal infiltrates in a proportion of healing
lesions, thus suggesting that HMGB1 might be a media-
tor of both early and late inflammation and may partici-
pate in the inflammatory process over longer periods of
time.
In a recent study by Bruchfeld and colleagues [16],
increased serum levels and renal tissue expression of
HMGB1 were demonstrated in ANCA-associated vascu-
litis with renal involvement. In that study, high baseline
serum levels of HMGB1 decreased significantly after
treatment, and in contrast to our findings in LN, a more
distinct histopathological response and a more distinct
clinical response were demonstrated. These findings are
consistent with other studies showing that patients with
LN, even patients with quiescent clinical pictures, still
may have histopathological inflammatory activity after
induction treatment [30,31]. Of note, less than half of
the patients in the present study were regarded as renal
responders according to the definition used. Our obser-
vation that serum HMGB1 remained significantly ele-
vated combined with persistent expression in renal
tissue at follow-up may reflect an ongoing inflammatory
activity in patients with LN despite immunosuppressive
therapy. The findings in patients with vasculitis are of
particular interest since LN with a focal segmental glo-
merular pattern (WHO class III), which had the highest
HMGB1 levels in our study, has been considered to
Table 2 Serum levels of HMGB1 in 20 patients
Baseline Follow-up
Patient HMGB1 WHO AI CI U-prot Crea HMGB1 WHO AI CI U-prot Crea
1 19.8 IV 8 0 0.0 66 34.1 I 0 0 0.0 78
2 84.8 IV 8 1 0.2 74 60.6 III 9 1 0.3 78
3 88.4 IV 12 1 1.9 185 89.6 IV 4 3 1.6 86
4 37.1 IV 9 1 3.7 89 27.9 II 2 0 0.9 86
5 29.6 III 5 0 1.3 77 40.3 V 1 2 1.6 87
6 87.9 IV 13 3 1.0 94 71.4 III 4 3 0.4 86
7 86.8 IV 6 0 2.1 64 29.3 II 1 1 3.4 60
8 98.1 IV 12 6 4.9 284 72.6 II 2 8 1.0 306
9 125.9 IV 6 2 1.5 167 109.8 II 1 6 0.1 72
10 120.4 IV 3 0 1.4 90 77.9 II 2 4 0.1 78
11 113.8 III 7 0 1.0 129 128.1 II 1 1 0.1 105
12 126.4 III/V 3 0 3.5 52 129.7 V 2 2 0.7 54
13 130 III 5 1 0.1 70 142.7 II 0 4 0.0 48
14 59.4 IV 6 1 0.3 82 61.7 IV 10 1 2.1 80
15 128.2 III 5 1 1.8 66 148.4 II 1 1 1.8 74
16 155 III 5 5 0.8 53 117.9 II 2 0 0.3 61
17 155.9 IV 5 0 4.8 96 145.9 V 1 0 0 74
18 159.9 III/V 4 0 0.2 53 181.5 V 1 0 0 68
19 158.9 III 5 0 0.3 52 159.9 III 3 1 0.1 66
20 202.4 III 5 1 1.1 60 183.9 III 4 1 0.5 68
Serum levels of high-mobility group box 1 protein (HMGB1) (expressed as nanograms per milliliter), histopathological findings, and renal activity at baseline and
follow-up are shown. Creatinine (crea) is expressed as micromoles per liter. AI, activity index; CI, chronicity index, u-prot; 24-hour urine albumin excretion; WHO,
World Health Organization.
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Figure 4 Expression of extranuclear HMGB1 protein in lupus nephritis (LN). Representative micrographs illustrate paraffin-embedded kidney
biopsies displaying immunohistochemical diaminobenzidine brown staining of HMGB1. (A) A baseline kidney biopsy from a patient with active
World Health Organization (WHO) class V LN, magnified in (B), demonstrates that an abundant HMGB1 staining is located predominantly
outlining the endothelium but also expressed in the mesangium (arrow). (C) The expression of HMGB1 is less pronounced in a repeat biopsy
(still classified as WHO V) of the same patient and is magnified in (D). The staining is now most evident outlining the endothelium but is also
found in the brush border of tubular cells. (E) A baseline biopsy from a patient with active class IV LN, magnified in (F), demonstrates that an
abundant HMGB1 expression is located outlining the endothelium. (G) A repeat biopsy in a patient with WHO class II after immunosuppressive
treatment, magnified in (H), illustrates that HMGB1 is still evident in glomeruli. (I) A baseline biopsy from a patient with WHO class III, magnified
in (J), demonstrates that an abundant HMGB1 staining is evident predominantly outlining the glomerular endothelium but also expressed in the
mesangium. (K) HMGB1 expression is still evident in a repeat biopsy (still classified as WHO III) of the same patient, magnified in (L), but is not
as strong as in the baseline biopsy. (M) A consecutive section from the same patient is stained with irrelevant isotype control antibody. In
kidney tissue from a healthy control, HMGB1 expression was predominantly negative or, if present, is restricted to the cell nuclei (N). Original
magnifications: 100× (A,C,E,G,I,K,M,N) and 250× (B,D,F,H,J,L). HMGB1, high-mobility group box 1 protein.
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have features and possibly immune mechanisms similar
to those of lesions of systemic vasculitis [32] in compari-
son with the more widespread global pattern character-
ized by more pronounced immune depositions seen in
patients with class IV. The difference observed in
HMGB1 levels when focal and diffuse proliferative
nephritis were compared may suggest differences in
pathogenic mechanisms and deserves further studies.
In the study by Abdulahad and colleagues [22], a cor-
relation between serum HMGB1 and proteinuria was
shown in active SLE patients having some degree of
proteinuria but was not confirmed in our study on
patients with active biopsy-proven LN only. The two
study populations may not be fully comparable, how-
ever. Although we could confirm the finding of elevated
HMGB1 levels in patients with LN as determined by
Western blot, the methods used in the two studies may
not be fully comparable (whole serum in the study by
Abdulahad and colleagues [22] in comparison with low
molecular serum components in the present study).
This methodological issue may have contributed to the
discrepancies regarding circulating HMGB1 and disease
activity between the two studies. Further studies would
be of interest to determine the optimal method for
HMGB1 determination in patients with LN.
Although HMGB1 levels have been shown to correlate
inversely with renal function in patients with chronic
kidney disease [17], no such correlation was found in
our study or in the previous study of patients with SLE
[22]. HMGB1 has been proposed to be involved in the
pathogenesis of SLE, and several biological properties of
HMGB1 are currently of major interest in SLE research
[8]. Inappropriate apoptosis is regarded as a key event in
the pathogenesis of SLE. Nuclear autoantigens from not
properly cleared apoptotic cells may be excessively pre-
sented to the immune system, resulting in loss of self-
tolerance and generation of nuclear autoantibodies [33].
HMGB1 released from apoptotic cells may therefore be
of special interest in SLE. In primary apoptosis, there is
almost no release of HMGB1; however, in conditions
with inappropriate clearance of apoptotic material,
apoptotic cells may undergo secondary necrosis leading
to HMGB1 release [34,35]. HMGB1 has been demon-
strated to bind to the chromatin of cells during apopto-
sis and to remain bound to nucleosomes when released
from apoptotic cells. Furthermore, HMGB1-nuclesome
complexes have recently been demonstrated to induce
the production of proinflammatory cytokines from
macrophages and dendritic cells and to induce anti-
dsDNA and anti-histone IgG responses and therefore
may play a central role in breaking tolerance against
nuclear antigens [36]. In that study, circulating
HMGB1-nucleosome complexes were detected in serum
from patients with SLE but not in healthy controls.
Previous studies have demonstrated high levels of
anti-HMGB1 antibodies in patients with SLE [22,37].
This finding raises the possibility that the monoclonal
anti-HMGB1 antibody used for tissue staining could
have difficulties in binding to HMGB1 if the epitope
was already occupied by deposited anti-HMGB1 antibo-
dies. This could possibly contribute to underestimating
the local renal expression of HMGB1 and, if so, could
explain why there were no clear differences in HMGB1
expression in the most proliferative inflammatory lesions
in comparison with less affected glomeruli.
Biomarkers available for assessing renal activity and
classification, response to therapy, remission, and flares
are insufficient in SLE and do not always reflect the
actual inflammatory activity in the renal tissue [30,38].
Although renal biopsy is regarded as the ‘gold standard’
for assessing renal activity [39], there is a need for new
biomarkers for evaluation of disease activity in LN. In
the present study, we were not able to determine
whether serum levels of HMGB1 could be used for
monitoring of renal disease activity per se but found
persistently elevated levels of serum as well as tissue
expression, suggesting that HMGB1 is an important
inflammatory mediator in LN. To determine whether a
more pronounced reduction of HMBG1 levels can be
achieved in a less active phase of LN, more long-term
studies with sequential serum HMGB1 determination
and repeat biopsies will be required, however.
As therapeutic targeting of HMGB1 has been found to
be protective against tissue injury in various preclinical
inflammatory disease models (reviewed in [40]),
HMGB1 blocking may be of future interest in the devel-
opment of new treatment strategies in autoimmune dis-
ease and also in SLE. As our study was of limited size,
additional extended studies will be required to study the
role of HMGB1 as a biomarker for renal disease activity
in patients with lupus.
Conclusions
The increased tissue staining for HMGB1, most pro-
nounced outlining the endothelium and in the mesan-
gium, clearly indicates a role for HMGB1 in the
inflammatory process of LN. Serum levels of HMGB1
were significantly increased in patients with LN and
remained elevated after induction treatment, possibly
reflecting persistent inflammatory activity despite immu-
nosuppressive therapy.
Abbreviations
ANCA: anti-neutrophilic cytoplasmatic antibody; anti-dsDNA: anti-double-
stranded DNA; BILAG: British Isles lupus assessment group; GFR: glomerular
filtration rate; HMGB1: high-mobility group box 1 protein; IL: interleukin; LN:
lupus nephritis; SLE: systemic lupus erythematosus; WHO: World Health
Organization.
Zickert et al. Arthritis Research & Therapy 2012, 14:R36
http://arthritis-research.com/content/14/1/R36
Page 8 of 10
Acknowledgements
Financial support was provided by a grant from King Gustaf V’s 80th
Birthday Fund, the Karolinska Institute Foundation, the Swedish Association
against Rheumatism, the Swedish Medical Research Council, Åke Wiberg’s
Foundation, and the Swedish Kidney Association and through the regional
agreement on medical training and clinical research (ALF) between
Stockholm County Council and Karolinska Institute.
Author details
1Department of Medicine, Unit of Rheumatology, D2:00 Solna, Karolinska
University Hospital, Karolinska Institute, S-171 76 Stockholm, Sweden.
2Women’s and Children’s Health, Astrid Lindgren Children’s Hospital, Solna,
Karolinska University Hospital, Karolinska Institute, S-171 76 Stockholm,
Sweden. 3Department of Pathology and Cytology, Solna, Karolinska
University Hospital, Karolinska Institute, S-171 76 Stockholm, Sweden.
4Laboratory of Biomedical Sciences, Feinstein Institute for Medical Research,
350 Community Drive, Manhasset, NY 11030, USA. 5Department of Renal
Medicine, K56 Huddinge, Karolinska University Hospital, Karolinska Institute,
S-141 86 Stockholm, Sweden.
Authors’ contributions
AZ participated in patient characterization, acquisition of data, statistical
analyses, interpretation of results, and manuscript writing. KP participated in
immunohistochemistry staining, interpretation of results, and manuscript
writing. BS participated in evaluation of renal biopsies and interpretation of
results of HMGB1 tissue staining. SC and KJT were responsible for serum
HMGB1 measurement and interpretation of data. AB participated in
interpretation of results and manuscript writing. IG participated in study
design, interpretation of results, and manuscript writing. All authors were
involved in revising the manuscript critically for content and read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 17 May 2011 Revised: 4 January 2012
Accepted: 20 February 2012 Published: 20 February 2012
References
1. Rahman A, Isenberg DA: Systemic lupus erythematosus. N Engl J Med
2008, 358:929-939.
2. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejia JC,
Aydintug AO, Chwalinska-Sadowska H, de Ramon E, Fernández-Nebro A,
Galeazzi M, Valen M, Mathieu A, Houssiau F, Caro N, Alba P, Ramos-
Casals M, Ingelmo M, Hughes GR, European Working Party on Systemic
Lupus Erythematosus: Morbidity and mortality in systemic lupus
erythematosus during a 10-year period: a comparison of early and late
manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003,
82:299-308.
3. Bianchi ME, Beltrame M, Paonessa G: Specific recognition of cruciform
DNA by nuclear protein HMG1. Science 1989, 243:1056-1059.
4. Muller S, Ronfani L, Bianchi ME: Regulated expression and subcellular
localization of HMGB1, a chromatin protein with a cytokine function. J
Intern Med 2004, 255:332-343.
5. Voll RE, Urbonaviciute V, Furnrohr B, Herrmann M, Kalden JR: The role of
high-mobility group box 1 protein in the pathogenesis of autoimmune
diseases. Curr Rheumatol Rep 2008, 10:341-342.
6. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ: HMGB1 as a DNA-
binding cytokine. J Leukoc Biol 2002, 72:1084-1091.
7. Pisetsky DS, Erlandsson-Harris H, Andersson U: High-mobility group box
protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic
disease. Arthritis Res Ther 2008, 10:209.
8. Andersson U, Harris HE: The role of HMGB1 in the pathogenesis of
rheumatic disease. Biochim Biophys Acta 2010, 1799:141-148.
9. Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by
necrotic cells triggers inflammation. Nature 2002, 418:191-195.
10. Wang H, Yang H, Tracey KJ: Extracellular role of HMGB1 in inflammation
and sepsis. J Intern Med 2004, 255:320-331.
11. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-
Harris H, Janson A, Kokkola R, Zhang M, Yang H, Tracey KJ: High mobility
group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis
in human monocytes. J Exp Med 2000, 192:565-570.
12. Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala HM,
Erlandsson-Harris H, Andersson U, Yang H, Tracey KJ, Andersson J,
Palmblad JE: High mobility group 1 B-box mediates activation of human
endothelium. J Intern Med 2003, 254:375-385.
13. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G,
Tracey KJ, Lee ML, Andersson J, Tokics L, Treutiger CJ: Persistent elevation
of high mobility group box-1 protein (HMGB1) in patients with severe
sepsis and septic shock. Crit Care Med 2005, 33:564-573.
14. Kokkola R, Sundberg E, Ulfgren AK, Palmblad K, Li J, Wang H, Ulloa L,
Yang H, Yan XJ, Furie R, Chiorazzi N, Tracey KJ, Andersson U, Harris HE:
High mobility group box chromosomal protein 1: a novel
proinflammatory mediator in synovitis. Arthritis Rheum 2002, 46:2598-2603.
15. Goldstein RS, Bruchfeld A, Yang L, Qureshi AR, Gallowitsch-Puerta M,
Patel NB, Huston BJ, Chavan S, Rosas-Ballina M, Gregersen PK, Czura CJ,
Sloan RP, Sama AE, Tracey KJ: Cholinergic anti-inflammatory pathway
activity and High Mobility Group Box-1 (HMGB1) serum levels in
patients with rheumatoid arthritis. Mol Med 2007, 13:210-215.
16. Bruchfeld A, Wendt M, Bratt J, Qureshi AR, Chavan S, Tracey KJ, Palmblad K,
Gunnarsson I: High-mobility group box-1 protein (HMGB1) is increased in
antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis
with renal manifestations. Mol Med 2011, 17:29-35.
17. Bruchfeld A, Qureshi AR, Lindholm B, Barany P, Yang L, Stenvinkel P,
Tracey KJ: High Mobility Group Box Protein-1 correlates with renal
function in chronic kidney disease (CKD). Mol Med 2008, 14:109-115.
18. Urbonaviciute V, Furnrohr BG, Weber C, Haslbeck M, Wilhelm S,
Herrmann M, Voll RE: Factors masking HMGB1 in human serum and
plasma. J Leukoc Biol 2007, 81:67-74.
19. Jiang W, Pisetsky DS: Expression of high mobility group protein 1 in the
sera of patients and mice with systemic lupus erythematosus. Ann
Rheum Dis 2008, 67:727-728.
20. Li J, Xie H, Wen T, Liu H, Zhu W, Chen X: Expression of high mobility
group box chromosomal protein 1 and its modulating effects on
downstream cytokines in systemic lupus erythematosus. J Rheumatol
2010, 37:766-775.
21. Barkauskaite V, Ek M, Popovic K, Harris HE, Wahren-Herlenius M, Nyberg F:
Translocation of the novel cytokine HMGB1 to the cytoplasm and
extracellular space coincides with the peak of clinical activity in
experimentally UV-induced lesions of cutaneous lupus erythematosus.
Lupus 2007, 16:794-802.
22. Abdulahad DA, Westra J, Bijzet J, Limburg PC, Kallenberg CG, Bijl M: High
mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their
relation to disease characteristics in systemic lupus erythematosus.
Arthritis Res Ther 2011, 13:R71.
23. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG,
Talal N, Winchester RJ: The 1982 revised criteria for the classification of
systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
24. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate
method to estimate glomerular filtration rate from serum creatinine: a
new prediction equation. Modification of Diet in Renal Disease Study
Group. Ann Intern Med 1999, 130:461-470.
25. Churg J, Bernstein J, Glassock RJ: Renal Disease: Classification and Atlas of
Glomerular Diseases. 2 edition. New York, Tokyo: Igakuso Shoin; 1995.
26. Austin HA, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH,
Decker JL, Balow JE: Prognostic factors in lupus nephritis. Contribution of
renal histologic data. Am J Med 1983, 75:382-391.
27. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML,
Symmons DP, Viner N, Zoma A: The BILAG index: a reliable and valid
instrument for measuring clinical disease activity in systemic lupus
erythematosus. Q J Med 1993, 86:447-458.
28. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, D’Cruz D,
Griffiths B, Khamashta M, Maddison P McHugh N, Snaith M, The LS, Yee CS,
Zoma A, Gordon C: BILAG 2004. Development and initial validation of an
updated version of the British Isles Lupus Assessment Group’s disease
activity index for patients with systemic lupus erythematosus.
Rheumatology (Oxford) 2005, 44:902-906.
29. Yee CS, Farewell V, Isenberg DA, Griffiths B, Teh LS, Bruce IN, Ahmad Y,
Rahman A, Prabu A, Akil M, McHugh N, Edwards C, D’Cruz D,
Khamashta MA, Maddison P, Gordon C: The BILAG-2004 index is sensitive
Zickert et al. Arthritis Research & Therapy 2012, 14:R36
http://arthritis-research.com/content/14/1/R36
Page 9 of 10
to change for assessment of SLE disease activity. Rheumatology (Oxford)
2009, 48:691-695.
30. Gunnarsson I, Sundelin B, Heimburger M, Forslid J, van Vollenhoven R,
Lundberg I, Jacobson SH: Repeated renal biopsy in proliferative lupus
nephritis–predictive role of serum C1q and albuminuria. J Rheumatol
2002, 29:693-699.
31. Hill GS, Delahousse M, Nochy D, Remy P, Mignon F, Mery JP, Bariety J:
Predictive power of the second renal biopsy in lupus nephritis:
significance of macrophages. Kidney Int 2001, 59:304-316.
32. Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J:
Significance of histologic patterns of glomerular injury upon long-term
prognosis in severe lupus glomerulonephritis. Kidney Int 2001,
59:2156-2163.
33. Janko C, Schorn C, Grossmayer GE, Frey B, Herrmann M, Gaipl US,
Munoz LE: Inflammatory clearance of apoptotic remnants in systemic
lupus erythematosus (SLE). Autoimmun Rev 2008, 8:9-12.
34. Bell CW, Jiang W, Reich CF, Pisetsky DS: The extracellular release of
HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006, 291:
C1318-1325.
35. Kruse K, Janko C, Urbonaviciute V, Mierke CT, Winkler TH, Voll RE, Schett G,
Munoz LE, Herrmann M: Inefficient clearance of dying cells in patients
with SLE: anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other
players. Apoptosis 2010, 15:1098-1113.
36. Urbonaviciute V, Furnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F,
Bianchi ME, Kirschning C, Wagner H, Manfredi AA, Kalden JR, Schett G,
Rovere-Querini P, Herrmann M, Voll RE: Induction of inflammatory and
immune responses by HMGB1-nucleosome complexes: implications for
the pathogenesis of SLE. J Exp Med 2008, 205:3007-3018.
37. Hayashi A, Nagafuchi H, Ito I, Hirota K, Yoshida M, Ozaki S: Lupus
antibodies to the HMGB1 chromosomal protein: epitope mapping and
association with disease activity. Mod Rheumatol 2009, 19:283-292.
38. Christopher-Stine L, Siedner M, Lin J, Haas M, Parekh H, Petri M, Fine DM:
Renal biopsy in lupus patients with low levels of proteinuria. J Rheumatol
2007, 34:332-335.
39. Gordon C, Jayne D, Pusey C, Adu D, Amoura Z, Aringer M, Ballerin J,
Cervera R, Calvo-Alén J, Chizzolini C, Dayer J, Doria A, Ferrario F, Floege J,
Guillevin L, Haubitz M, Hiepe F, Houssiau F, Lesavre P, Lightstone L,
Meroni P, Meyer O, Moulin B, O’Reilly K, Praga M, Schulze-Koops H, Sinico R,
Smith K, Tincani A, Vasconcelos C, et al: European consensus statement
on the terminology used in the management of lupus
glomerulonephritis. Lupus 2009, 18:257-263.
40. Yang H, Tracey KJ: Targeting HMGB1 in inflammation. Biochim Biophys
Acta 2010, 1799:149-156.
doi:10.1186/ar3747
Cite this article as: Zickert et al.: Renal expression and serum levels of
high mobility group box 1 protein in lupus nephritis. Arthritis Research &
Therapy 2012 14:R36.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zickert et al. Arthritis Research & Therapy 2012, 14:R36
http://arthritis-research.com/content/14/1/R36
Page 10 of 10
